SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or…
64 Years Old With $1.1 Million in a Traditional IRA. Here’s Where I’m Allocating Capital
Quick Read KO and ABBV anchor the portfolio at 25% each, rated Very Safe with payout ratios under…
US stocks drift near their records after oil prices fall
NEW YORK (AP) — U.S. stocks are drifting near their records in mixed trading Monday after trading resumed…
3 Ridiculously Cheap Healthcare Stocks to Buy in June
Quick Read NVO sits 44% below its 52-week high with a price-to-free-cash-flow of 5 and a free cash…
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Investors seeking reliable dividends and healthcare exposure often find themselves choosing between AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE). Both…
2 High-Yield Healthcare Stocks to Buy Before They Raise Payouts
It’s safe to say the healthcare sector isn’t renowned as a repository of dividend-paying companies. Yet some not…
Best Healthcare Stocks to Buy After the Market Pullback
Equity markets have moved in the wrong direction over the past three weeks. They may not rebound and…
If You Have $500,000 Saved at 60, Here’s The Sort of Monthly Income You Can Count On
Verizon (VZ) yields 5.4% at its current price, paying $0.69 per quarter and offering higher current income for…
The Best Healthcare Stocks to Buy With $5,000 in 2026 and Hold Forever
Eli Lilly has outstanding growth prospects thanks to its leadership in its core therapeutic area. AbbVie’s immunosuppressant portfolio…
Buying This Healthcare Stock Could Make You a Millionaire Retiree
AbbVie has a solid business capable of performing well even in bad times. The company has proven that…
My Top 3 Healthcare Stocks to Buy in 2026
With its diverse product line, AbbVie is a terrific dividend stock with a solid underlying business. Eli Lilly…
Here Are 2 Affordable Healthcare Stocks to Buy Heading Into 2026
One of these pharmaceutical leaders overcame a major obstacle and has a strong outlook. The other is actively…